Raghida Adib Bukhalid from Cambridge, MA, age 63

Raghida Bukhalid Phones & Addresses

Cambridge, MA
80 Ferdinand St, Melrose, MA 02176 • 7813970356
10 Summer St, Malden, MA 02148 • 7813970356
107 Pine Tree Rd, Ithaca, NY 14850 • 6072737015
10 Summer St APT 606, Malden, MA 02148

Work

Company:

Mersana therapeutics
Jan 2018
Position:

Associate director, project lead

Education

School / High School:

Harvard University
Specialities:

Biology

Skills

Oncology • Life Sciences • Drug Development • Molecular Biology • Cell Culture • Biotechnology • Drug Discovery • Biochemistry • Cross Functional Team Leadership • Biomarker Discovery • Assay Development • Monoclonal Antibodies • Personalized Medicine

Industries

Biotechnology

Resumes

Associate Director, Project Lead

view source

Location:

Cambridge, MA

Industry:

Biotechnology

Work:

Mersana Therapeutics
Associate Director, Project Lead
Merrimack 2013 - 2014
Principal Scientist, Infectious Disease, Project Lead
Merrimack 2009 - 2013
Principal Scientist, Oncology Project Lead
Merrimack 2007 - 2009
Senior Research Scientist

Education:

Harvard University
Cornell University
Doctorates, Doctor of Philosophy, Microbiology, Philosophy

Skills:

Oncology
Life Sciences
Drug Development
Molecular Biology
Cell Culture
Biotechnology
Drug Discovery
Biochemistry
Cross Functional Team Leadership
Biomarker Discovery
Assay Development
Monoclonal Antibodies
Personalized Medicine

Us Patents

Monoclonal And Oligoclonal Anti-Egfr Antibodies For Use In The Treatment Of Tumors Expressing Predominantly High Affinity Egfr Ligands Or Tumors Expressing Predominantly Low Affinity Egfr Ligands
view source
US Patent:

20120308576, Dec 6, 2012
Filed:

Jun 4, 2012
Appl. No.:

13/488270
Inventors:

Raghida BUKHALID - Melrose MA, US
Ulrik NIELSEN - Quincy MA, US
Shannon WERNER - Belmont MA, US
Jeffrey David KEARNS - Arlington MA, US
Assignee:

MERRIMACK PHARMACEUTICALS, INC. - Cambridge MA
International Classification:

C07K 16/28
A61P 35/00
A61K 39/395
C12Q 1/68
G01N 33/574
US Classification:

4241431, 435 611, 435 612, 435 794, 435 723, 53038822
Abstract:

Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-EGFR monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations.

Antibodies Against Epidermal Growth Factor Receptor (Egfr) And Uses Thereof
view source
US Patent:

20110287002, Nov 24, 2011
Filed:

May 4, 2011
Appl. No.:

13/100920
Inventors:

Raghida BUKHALID - Melrose MA, US
Michael FELDHAUS - Grantham NH, US
Anne KING - Cambridge MA, US
Neeraj KOHLI - Brighton MA, US
Eric KRAULAND - Lebanon NH, US
Assignee:

ADIMAB, LLC - Lebanon NH
International Classification:

A61K 39/395
C07K 16/28
US Classification:

4241331, 4241431, 4241781, 5303873, 53038822, 5303911
Abstract:

Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.

Antibody Drug Conjugates Comprising Sting Agonists
view source
US Patent:

20220378749, Dec 1, 2022
Filed:

Apr 2, 2021
Appl. No.:

17/221341
Inventors:

- Cambridge MA, US
Keith W. BENTLEY - Everett MA, US
Raghida A. BUKHALID - Medford MA, US
Marc I. DAMELIN - Needham MA, US
Eugene W. KELLEHER - Wellesley MA, US
Timothy B. LOWINGER - Carlisle MA, US
Joshua D. THOMAS - Natick MA, US
Dorin TOADER - Cambridge MA, US
Ling XU - Brookline MA, US
Liping YANG - Arlington MA, US
International Classification:

A61K 31/4184
A61K 47/54
A61K 47/65
A61K 47/60
A61K 47/55
A61K 45/06
A61K 47/68
A61P 35/00
A61K 31/422
A61K 31/437
A61K 31/428
Abstract:

The present disclosure provides scaffolds and antibody-drug conjugates (ADCs) comprising a stimulator of interferon genes (STING). The present disclosure also provides uses of the ADCs in treatment, e.g., treatment of cancer.

Raghida Adib Bukhalid